Business Context and Reporting Period
Company: Repro-Med Systems, Inc. (Note: Input metadata referenced "KORU Medical Systems," but the filing text identifies the registrant as Repro-Med Systems, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: February 28, 2011
Business Overview: The Company designs, manufactures, and markets proprietary medical devices, primarily the FREEDOM60(R) Syringe Infusion System for ambulatory infusion and the RES-Q-VAC(R) Emergency Medical Suction System. The Company is a smaller reporting company incorporated in New York.
Key Financial Metrics
| Metric | Fiscal Year 2011 | Fiscal Year 2010 |
|---|---|---|
| Net Sales | $4,920,723 | $3,774,873 |
| Gross Profit Margin | 66.3% | 66.5% |
| Net Operating Profit | $1,194,829 | $721,519 |
| Net Income | $704,085 | $889,444 |
| Net Cash Provided by Operations | $1,028,465 | $382,298 |
| Total Assets | $3,434,688 | $2,987,679 |
| Total Liabilities | $954,228 | $1,298,785 |
| Cash and Cash Equivalents | $1,322,250 | $813,383 |
| Long-Term Debt | $482,800 | $623,739 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 30.4% to $4.92 million, driven primarily by a 44.2% increase in FREEDOM60(R) sales ($4.04 million vs. $2.81 million). This growth is attributed to increased usage in subcutaneous immune globulin (SCIG) and antibiotic markets.
- Profitability: While Net Operating Profit increased significantly (65.6%), Net Income decreased 20.8% to $704,085. This decline was caused by a shift from an income tax benefit of $226,984 in 2010 to a tax expense of $489,034 in 2011, following the reduction of the valuation allowance on deferred tax assets in the prior year.
- Cash Flow: Net cash provided by operating activities more than doubled to $1.03 million, reflecting improved pre-tax income and working capital management.
- Debt Reduction: Total liabilities decreased by approximately $344,500, largely due to the repayment of a $100,000 loan from the President and reductions in related party notes.
Guidance, Outlook, and Risks
- Product Outlook: Management anticipates continued sales growth for the FREEDOM60(R) system as the SCIG market develops. The Company received FDA clearance in May 2011 for new subcutaneous needle sets and plans to launch domestic marketing for these sets, expecting to expand market share.
- Liquidity: Management believes current resources and increased cash flow are sufficient to meet liquidity needs for the next twelve months.
- Key Risks:
- Reimbursement: Sales are heavily dependent on Medicare reimbursement codes (specifically E0779). Changes in reimbursement policies could adversely affect sales.
- Key Personnel: The Company is dependent on Andrew Sealfon (President, CEO, CFO, and R&D head). There is no life insurance on his life, and replacement may be difficult.
- Competition: Potential entry of competitors with greater resources or new drug formulations (e.g., Hizentra) that alter market dynamics.
- Regulatory: Ongoing compliance with FDA regulations is critical; failure to comply could result in penalties or recalls.
Investor Verification Checklist
- Reimbursement Stability: Verify the continued validity of Medicare HCPCS code E0779 for the FREEDOM60(R) pump and any potential changes in reimbursement rates.
- New Product Adoption: Monitor the commercial success and market acceptance of the new FDA-cleared subcutaneous needle sets following their domestic launch.
- Key Person Risk: Assess the succession plan and contingency measures regarding the health and availability of Andrew Sealfon.
- Related Party Transactions: Review the terms of the building lease (owned by a director) and aircraft lease (owned by a company controlled by the President) to ensure arm's-length pricing.
- Debt Maturities: Confirm the Company's ability to service remaining long-term debt, primarily the director loan maturing in 2021.